PRGO
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
2023-01-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when PERRIGO Co plc publishes a filing, an earnings call transcript or a press release.
Get PRGO alertsPatrick Lockwood-Taylor is recorded as CEO at PERRIGO Co plc (PRGO) since June 30, 2023. PERRIGO Co plc reported in an 8-K filed June 8, 2026 that Patrick Lockwood-Taylor resigned as member of the Board of Directors, effective June 7, 2026. The same filing states: “Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.” PERRIGO Co plc reported in an 8-K filed June 8, 2026 that Patrick Lockwood-Taylor resigned as President and Chief Executive Officer, effective June 7, 2026. The same filing states: “Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.” PERRIGO Co plc reported in an 8-K filed June 8, 2023 that Patrick Lockwood-Taylor was appointed President, CEO and director, effective June 30, 2023. The proxy statement of PERRIGO Co plc reports total compensation of $9,042,603 for Patrick Lockwood-Taylor in fiscal 2025, including a base salary of $1,223,333. Disclosed compensation is on record for 3 fiscal years. Patrick Lockwood-Taylor has spoken on 11 earnings calls and 1 other investor event across 1 company, most recently for PERRIGO Co plc on March 11, 2026. PERRIGO Co plc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at PERRIGO Co plc includes Albert A. Manzone (CEO and Board Member), Eduardo Bezerra (CFO), Charles Atkinson (General Counsel) and 7 others.
“On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors (the "Board") of Perrigo Company plc (the "Company").”
“Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.”
“On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors (the "Board") of Perrigo Company plc (the "Company").”
“Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.”
“Steady progress in challenging market environments impacts it first. However, our 3S plan to stabilize, streamline, and strengthen the company is helping us navigate these conditions and positioning the company for long-term growth.”
“2025 was a year of meaningful progress for Perica. We continue transforming the company into a world-class consumer health leader, and the results of that work are increasingly visible in the marketplace.”
“I'd like to begin by addressing recent category consumption trends across consumer health, which remain soft, reflecting broad short-term market pressures. Against this backdrop, Perrigo has delivered sustained share gains and advanced key initiatives under our Three-S plan to Stabilize, Streamline, and to Strengthen.”
“I'd like to start with a quick overview of the progress that we have made against our Three-S Plan, to Stabilize, Streamline, and Strengthen One Perrigo. We've accomplished a tremendous amount of work over the past 18 months to evolve into a more focused, agile, and scalable self-care organization.”
“I'd like to begin with an update on our progress against our Three-S Plan to Stabilize, Streamline and Strengthen Perrigo. Over the past 12 months, efforts to stabilize key parts of our business have yielded positive results.”
2023-06-30–present
2026-04-30–2026-06-07
2023-01-01–2026-06-07
Start not stated–2026-06-07
PRGO
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | PERRIGO Co plc (PRGO) | CEO, President | $1,223,333 | $9,042,603 |
| 2024 | PERRIGO Co plc (PRGO) | CEO, President | $1,200,000 | $7,794,829 |
| 2023 | PERRIGO Co plc (PRGO) | CEO, President | $604,615 | $6,067,969 |
“Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.”
PERRIGO Co plc (PRGO)“Mr. Lockwood-Taylor’s resignation is not related to the Company’s business, strategy, operations, financial reporting, or results of operations.”
PERRIGO Co plc (PRGO)